Evidence map›Paper›PMID 28368379›Full record

Trial reportBone marrow transplantation2017

Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.

S Yamasaki, R Suzuki, K Hatano, K Fukushima, H Iida, S Morishima, Y Suehiro, T Fukuda, N Uchida, H Uchiyama and 11 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 18 institutions in 1 country.

S YamasakiDepartment of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
R SuzukiDepartment of Oncology and Haematology, Shimane University Hospital, Izumo, Japan.
K HatanoDivision of Hematology and Cell Therapy, Jichi Medical University, Shimotsuke, Japan.
K FukushimaDivision of Hematology, Rinku General Medical Center, Izumisano, Japan.
H IidaDivision of Cell Therapy, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
S MorishimaDepartment of Hematology and Oncology, Fujita Health University School of Medicine, Toyoake, Japan.
Y SuehiroDepartment of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
T FukudaDivision of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
N UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
H UchiyamaDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
H IkedaDepartment of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University Hospital, Sapporo, Japan.
A YokotaDepartment of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan.
K TsukasakiHematology Division, National Cancer Center Hospital East, Kashiwa, Japan.
H YamaguchiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
J KurodaDivision of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
H NakamaeDepartment of Hematology, Osaka City University Hospital, Osaka, Japan.
Y AdachiDepartment of Internal Medicine, Japan Community Health Care Organization Kobe Central Hospital, Kobe, Japan.
K-I MatsuokaDivision of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Y NakamuraThird Department of Internal of Medicine, Yamaguchi University School of Medicine, Ube, Japan.
Y AtsutaDepartment of Healthcare Administration, Nagoya University Graduate School of Medicine and Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
J SuzumiyaDepartment of Oncology and Haematology, Shimane University Hospital, Izumo, Japan.
Shimane University Hospital · JPChiba Aoba Municipal Hospital · JPFujita Health University · JPJichi Medical University · JPKobe Central Hospital · JPKyoto first Red Cross hospital · JPKyoto Prefectural University of Medicine · JPNagoya University · JPNational Cancer Center Hospital East · JPNational Hospital Organization · JPNational Hospital Organization Kyushu Cancer Center · JPNational Kyushu Medical Center · JPNippon Medical School · JPOkayama University Hospital · JPOsaka City University Hospital · JPSapporo Medical University Hospital · JPToranomon Hospital · JPYamaguchi University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) represent severe late effects in patients receiving hematopoietic cell transplantation (HCT) for lymphoma. The choice between high-dose therapy with autologous HCT and allogeneic HCT with reduced-intensity conditioning remains controversial in patients with relapsed lymphoma. We retrospectively analyzed incidence and risk factors for the development of t-AML/MDS in lymphoma patients treated with autologous or allogeneic HCT. A total of 13 810 lymphoma patients who received autologous (n=9963) or allogeneic (n=3847) HCT between 1985 and 2012 were considered. At a median overall survival (OS) of 52 and 46 months in autologous and allogeneic HCT groups, respectively, lymphoma patients receiving autologous HCT (1.38% at 3 years after autologous HCT) had a significant risk for developing t-AML/MDS compared to allogeneic HCT (0.37% at 3 years after allogeneic HCT, P<0.001). Significant risk factors for the development of t-AML/MDS after autologous and allogeneic HCT were high-stage risk at HCT (P=0.04) or secondary malignancies (P<0.001) and receiving cord blood stem cell (P=0.03) or involved field radiotherapy (P=0.002), respectively. Strategies that carefully select lymphoma patients for autologous HCT, by excluding lymphoma patients with high-stage risk at HCT, may allow the identification of individual lymphoma patients at particular high risk for t-AML/MDS.

Indexed as

Hematopoietic Stem Cell TransplantationAdolescentAdultAgedAged, 80 and overAllograftsAutograftsFemaleFollow-Up StudiesHumansLeukemia, Myeloid, AcuteLymphomaMaleMiddle AgedMyelodysplastic SyndromesNeoplasms, Second Primary

Identifiers

PMID28368379
OpenAlexW2604915465

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.